Brief: Sensorion Announces Positive Results From Seliforant Phase 2A Study

Sensorion SA

14/12/2018 06:37

Dec 14 (Reuters) - SENSORION SA  ALSEN.PA :
    * SENSORION ANNOUNCES POSITIVE TOPLINE RESULTS FROM
SELIFORANT
PHASE 2A STUDY
    * STUDY SHOWED THAT SELIFORANT, IN CONTRAST TO MECLIZINE,
HAS NO
NEGATIVE CNS SIDE EFFECTS SUCH AS SEDATION, IMPAIRMENT OF MEMORY
AND COGNITIVE PERFORMANCE
    * NEXT MILESTONE IS PHASE 2 POC EFFICACY TRIAL READOUT IN
AUV IN
H2 2019

Source text for Eikon:  ID:nGNX6g1hLh 
Further company coverage:  ALSEN.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com;))